Cargando…

Acute peritoneal dialysis in the treatment of COVID-19-related acute kidney injury

The kidney is not typically the main target of severe acute respiratory syndrome coronavirus 2, but surprisingly, acute kidney injury (AKI) may occur in 4–23% of cases, whereas the dialysis management of AKI from coronavirus 2019 has not gained much attention. The severity of the pandemic has result...

Descripción completa

Detalles Bibliográficos
Autores principales: Ponce, Daniela, Balbi, André L, Durand, Jonathan B, Moretta, Gustavo, Divino-Filho, José C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7337686/
https://www.ncbi.nlm.nih.gov/pubmed/32695319
http://dx.doi.org/10.1093/ckj/sfaa102
_version_ 1783554557575430144
author Ponce, Daniela
Balbi, André L
Durand, Jonathan B
Moretta, Gustavo
Divino-Filho, José C
author_facet Ponce, Daniela
Balbi, André L
Durand, Jonathan B
Moretta, Gustavo
Divino-Filho, José C
author_sort Ponce, Daniela
collection PubMed
description The kidney is not typically the main target of severe acute respiratory syndrome coronavirus 2, but surprisingly, acute kidney injury (AKI) may occur in 4–23% of cases, whereas the dialysis management of AKI from coronavirus 2019 has not gained much attention. The severity of the pandemic has resulted in significant shortages in medical supplies, including respirators, ventilators and personal protective equipment. Peritoneal dialysis (PD) remains available and has been used in clinical practice for AKI for >70 years; however, it has been used on only a limited basis and therefore experience and knowledge of its use has gradually vanished, leaving a considerable gap. The turning point came in 2007, with a series of sequential publications providing solid evidence that PD is a viable option. As there was an availability constraint and a capacity limit of equipment/supplies in many countries, hemodialysis and convective therapies became alternatives. However, even these therapies are not available in many countries and their capacity is being pushed to the limit in many cities. Evidence-based PD experience lends support for the use of PD now.
format Online
Article
Text
id pubmed-7337686
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-73376862020-07-08 Acute peritoneal dialysis in the treatment of COVID-19-related acute kidney injury Ponce, Daniela Balbi, André L Durand, Jonathan B Moretta, Gustavo Divino-Filho, José C Clin Kidney J Editorial Comments The kidney is not typically the main target of severe acute respiratory syndrome coronavirus 2, but surprisingly, acute kidney injury (AKI) may occur in 4–23% of cases, whereas the dialysis management of AKI from coronavirus 2019 has not gained much attention. The severity of the pandemic has resulted in significant shortages in medical supplies, including respirators, ventilators and personal protective equipment. Peritoneal dialysis (PD) remains available and has been used in clinical practice for AKI for >70 years; however, it has been used on only a limited basis and therefore experience and knowledge of its use has gradually vanished, leaving a considerable gap. The turning point came in 2007, with a series of sequential publications providing solid evidence that PD is a viable option. As there was an availability constraint and a capacity limit of equipment/supplies in many countries, hemodialysis and convective therapies became alternatives. However, even these therapies are not available in many countries and their capacity is being pushed to the limit in many cities. Evidence-based PD experience lends support for the use of PD now. Oxford University Press 2020-06-30 /pmc/articles/PMC7337686/ /pubmed/32695319 http://dx.doi.org/10.1093/ckj/sfaa102 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Editorial Comments
Ponce, Daniela
Balbi, André L
Durand, Jonathan B
Moretta, Gustavo
Divino-Filho, José C
Acute peritoneal dialysis in the treatment of COVID-19-related acute kidney injury
title Acute peritoneal dialysis in the treatment of COVID-19-related acute kidney injury
title_full Acute peritoneal dialysis in the treatment of COVID-19-related acute kidney injury
title_fullStr Acute peritoneal dialysis in the treatment of COVID-19-related acute kidney injury
title_full_unstemmed Acute peritoneal dialysis in the treatment of COVID-19-related acute kidney injury
title_short Acute peritoneal dialysis in the treatment of COVID-19-related acute kidney injury
title_sort acute peritoneal dialysis in the treatment of covid-19-related acute kidney injury
topic Editorial Comments
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7337686/
https://www.ncbi.nlm.nih.gov/pubmed/32695319
http://dx.doi.org/10.1093/ckj/sfaa102
work_keys_str_mv AT poncedaniela acuteperitonealdialysisinthetreatmentofcovid19relatedacutekidneyinjury
AT balbiandrel acuteperitonealdialysisinthetreatmentofcovid19relatedacutekidneyinjury
AT durandjonathanb acuteperitonealdialysisinthetreatmentofcovid19relatedacutekidneyinjury
AT morettagustavo acuteperitonealdialysisinthetreatmentofcovid19relatedacutekidneyinjury
AT divinofilhojosec acuteperitonealdialysisinthetreatmentofcovid19relatedacutekidneyinjury